Nuvation Bio (Nuvation Bio) Accumulated Depreciation : $0.00 Mil (As of Sep. 2021)

View and export this data going back to 2020. Start your Free Trial

What is Nuvation Bio Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Nuvation Bio Accumulated Depreciation Historical Data

The historical data trend for Nuvation Bio's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Accumulated Depreciation Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Accumulated Depreciation

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Accumulated Depreciation	Get a 7-Day Free Trial			-	-	-	-	-

Nuvation Bio Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Nuvation Bio Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

N/A

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company. The company is engaged in developing therapeutic candidates for the unmet needs in oncology. The firm operates in pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates as treatments for cancer patients.